Search research articles
Contact Us
Filters
Showing results (81-90 of 102) with videos related to
Page
of 11
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
January 29, 2016
Dosing to rash?--The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash
Michael Steffens, Tanusree Paul, Vivien Hichert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 16, 2015
Enumeration and Molecular Characterization of Tumor Cells in Lung Cancer Patients Using a Novel In Vivo Device for Capturing Circulating Tumor Cells
Tobias M Gorges, Nicole Penkalla, Thomas Schalk, et al.
BMJ (Clinical Research Ed.)
|
May 31, 2012
Serum glucose levels for predicting death in patients admitted to hospital for community acquired pneumonia: prospective cohort study
Philipp M Lepper, Sebastian Ott, Eveline Nüesch, et al.
Respiration; International Review of Thoracic Diseases
|
October 27, 2022
Crossover Patient Outcomes for Targeted Lung Denervation in Moderate to Severe Chronic Obstructive Pulmonary Disease: AIRFLOW-2
Francesca Conway, James Tonkin, Arschang Valipour, et al.
Virulence
|
October 23, 2020
Respiratory ß-2-Microglobulin exerts pH dependent antimicrobial activity
Armin Holch, Richard Bauer, Lia-Raluca Olari, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 17, 2016
The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial
Martin Reck, Mark A Socinski, Alexander Luft, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
December 15, 2021
Prospective, Noninterventional Study of Nivolumab in Real-world Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Chemotherapy (ENLARGE-Lung)
Martin Sebastian, Andreas Gröschel, Sylvia Gütz, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 20, 2017
A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer
Thomas Wehler, Michael Thomas, Christian Schumann, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 15, 2016
Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study)
Michael Kreuter, Johan Vansteenkiste, Jürgen R Fischer, et al.
The Lancet. Oncology
|
June 6, 2015
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial
Nick Thatcher, Fred R Hirsch, Alexander V Luft, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 102) with videos related to
Sort By:
Page
of 11
European Journal of Cancer (Oxford, England : 1990)
|
January 29, 2016
Dosing to rash?--The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash
Michael Steffens, Tanusree Paul, Vivien Hichert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 16, 2015
Enumeration and Molecular Characterization of Tumor Cells in Lung Cancer Patients Using a Novel In Vivo Device for Capturing Circulating Tumor Cells
Tobias M Gorges, Nicole Penkalla, Thomas Schalk, et al.
BMJ (Clinical Research Ed.)
|
May 31, 2012
Serum glucose levels for predicting death in patients admitted to hospital for community acquired pneumonia: prospective cohort study
Philipp M Lepper, Sebastian Ott, Eveline Nüesch, et al.
Respiration; International Review of Thoracic Diseases
|
October 27, 2022
Crossover Patient Outcomes for Targeted Lung Denervation in Moderate to Severe Chronic Obstructive Pulmonary Disease: AIRFLOW-2
Francesca Conway, James Tonkin, Arschang Valipour, et al.
Virulence
|
October 23, 2020
Respiratory ß-2-Microglobulin exerts pH dependent antimicrobial activity
Armin Holch, Richard Bauer, Lia-Raluca Olari, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 17, 2016
The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial
Martin Reck, Mark A Socinski, Alexander Luft, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
December 15, 2021
Prospective, Noninterventional Study of Nivolumab in Real-world Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Chemotherapy (ENLARGE-Lung)
Martin Sebastian, Andreas Gröschel, Sylvia Gütz, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 20, 2017
A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer
Thomas Wehler, Michael Thomas, Christian Schumann, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 15, 2016
Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study)
Michael Kreuter, Johan Vansteenkiste, Jürgen R Fischer, et al.
The Lancet. Oncology
|
June 6, 2015
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial
Nick Thatcher, Fred R Hirsch, Alexander V Luft, et al.
Page
of 11